Pharming
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Netherlands · 201-500 Employees
View Company Info for Free
Overview
Headquarters
Vondellaan 47, Leiden, South Holland, 23...Phone Number
+31 715247400Website
www.pharming.comRevenue
$362.3 MillionStock Symbol
PHARMIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Pharming
Pharming Group N.V. is a global biopharmaceutical company focused on developing and commercializing innovative protein replacement therapies and precision medicines. Their mission is to serve the unserved rare disease patient community by addressing unmet medical needs. The company engages with various stakeholders including investors and partners to drive growth and innovation. They are committed to attracting talented individuals dedicated to improving the lives of patients.Explore more
Pharming Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Pharming your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Pharming recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Pharming, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Pharming
Website visits: Recent activity has been detected on your website
Click to see if Pharming had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Pharming has new funding data
Check out if Pharming is spiking on competitors!
Product Launch: Get notified when Pharming launches new products
Check if Pharming has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Company Profile Activity
Activity Insights
Pharming is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Pharming is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Pharming.
Pharming financials insights
Gather financial insights about Pharming, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Debt
$17M
2017
Debt
$100M
Pharming Tech Stack
A closer look at the technologies used by Pharming
See more technologies
Most Recent Scoops
Person-Based
Earnings, Finance
Person-Based
Product Launch, Pharmaceuticals
Open Position
Project
Pharming has identified 60 US patients between the ages of four and 11 as candidates for the pediatric Joenja indication, with approximately 50% in each of the higher and lower dose categories, and anticipates a patient uptake trajectory similar to that observed in the adult population following approval.
Pharmaceuticals, Clinical Operations
Project
Medical Research, Pharmaceuticals, Clinical Operations
Pharming News & Media
FDA approves Pharming’s Joenja® as first treatment for children with APDS in the U.S.
Pharming today announced that the U.S. FDA has approved its sNDA for Joenja® as first treatment for children with APDSPharming Group to participate in September investor conferences
Pharming Group to participate in investor conferences Sep. 14-15. H.C. Wainwright Growth Conference and Morgan Stanley Healthcare Conference in New York.Pharming announces commercial launch of Joenja (leniolisib) in Japan for adult and pediatric patients with APDS aged 4 and older
Leiden, the Netherlands, August 13, 2026: Pharming Group (Euronext Amsterdam: PHARM/Nasdaq: PHAR), today announced the commercial launch of Joenja (leniolisib) in Japan for adult and pediatric patients with activated PI3K delta syndrome (APDS) aged 4 years and older, following its inclusion on the Japan National Health Insurance (NHI) drug price list. With this launch, Japan is now the first market where Joenja is commercially available for children aged 4 to 11.Pharming Group (PHAR) Securities Investigation Notice - Levi & Korsinsky
Pharming Group told investors to expect up to $425 million in 2026 revenue. The Company now expects as little as $375 million -- and the stock lost 22% in a single session. NEW YORK, Aug. 7, 2026 /PRNewswire/ -- A 22% single-session decline hit Pharming Group (NASDAQ: PHAR) shareholders...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Pharming
Sign Up For FreeTo access detailed company insights
Pharming Group N.V. is a global biopharmaceutical company focused on developing and commercializing innovative protein replacement therapies and precision medicines. Their mission is to serve the unserved rare disease patient community by addressing unmet medical needs. The company engages with various stakeholders including investors and partners... Read More
